{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:09Z","timestamp":1793397909244,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007135","name":"University of Tennessee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","ajog.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ajog.2019.07.037","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T15:09:16Z","timestamp":1564585756000},"page":"83.e1-83.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Use of naltrexone in treating opioid use disorder in pregnancy"],"prefix":"10.1016","volume":"222","author":[{"given":"Craig V.","family":"Towers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2019.07.037_bib1","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths\u2013United States, 2013-2017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajog.2019.07.037_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1056\/NEJMra1802148","article-title":"Understanding links among opioid use, overdose, and suicide","volume":"380","author":"Bohnert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2019.07.037_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.15585\/mmwr.mm6709e1","article-title":"Vital signs: trends in emergency department visits for suspected opioid overdoses\u2013United States, July 2016-September 2017","volume":"67","author":"Vivolo-Kantor","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajog.2019.07.037_bib4","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs","volume":"372","author":"Tolia","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2019.07.037_bib5","series-title":"Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63, Executive Summary. HHS Publication No. (SMA) 18-5063EXSUMM","year":"2018"},{"key":"10.1016\/j.ajog.2019.07.037_bib6","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Opioid use and opioid use disorder in pregnancy: Committee Opinion No. 711","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1479-828X.2001.tb01322.x","article-title":"Obstetric and neonatal outcomes associated with maternal naltrexone exposure","volume":"41","author":"Hulse","year":"2001","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.0004-8666.2002.00104.x","article-title":"A\u00a0possible role for implantable naltrexone in the management of the high-risk pregnant heroin user","volume":"42","author":"Hulse","year":"2002","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.0004-8666.2002.548_14.x","article-title":"Using naltrexone implants in the management of the pregnant heroin user","volume":"42","author":"Hulse","year":"2002","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.0004-8666.2003.00121.x","article-title":"Naltrexone implant and blood naltrexone levels over pregnancy","volume":"43","author":"Hulse","year":"2003","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijgo.2003.10.001","article-title":"Methadone maintenance vs implantable naltrexone treatment in the pregnant heroin user","volume":"85","author":"Hulse","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2019.07.037_bib12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40265-017-0763-8","article-title":"A\u00a0retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine-, and non-opioid-exposed controls","volume":"77","author":"Kelty","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ajog.2019.07.037_bib13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s40265-017-0762-9","article-title":"A\u00a0retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls","volume":"77","author":"Kelty","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ajog.2019.07.037_bib14","unstructured":"Product Information. ReVia. Duramed Pharmaceuticals, 2013. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018932s017lbl.pdf. Last accessed January 24, 2019."},{"key":"10.1016\/j.ajog.2019.07.037_bib15","unstructured":"Product Information. Narcan. Duramed Pharmaceuticals, 2013. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/016636s052s054lbl.pdf. Last accessed January 24, 2019."},{"key":"10.1016\/j.ajog.2019.07.037_bib16","series-title":"Drugs in pregnancy and lactation","author":"Briggs","year":"2017"},{"key":"10.1016\/j.ajog.2019.07.037_bib17","doi-asserted-by":"crossref","first-page":"374.e1","DOI":"10.1016\/j.ajog.2016.03.015","article-title":"Detoxification from opiate drugs during pregnancy","volume":"215","author":"Bell","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib18","doi-asserted-by":"crossref","first-page":"e20180541","DOI":"10.1542\/peds.2018-0541","article-title":"Neonatal head circumference in newborns with neonatal abstinence syndrome","volume":"143","author":"Towers","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajog.2019.07.037_bib19","series-title":"Current therapy in neonatal-perinatal medicine","first-page":"264","article-title":"Neonatal abstinence","author":"Finnegan","year":"1985"},{"key":"10.1016\/j.ajog.2019.07.037_bib20","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/AOG.0000000000002046","article-title":"Methods for estimating the due date: Committee Opinion No. 700","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2019.07.037_bib21","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1542\/peds.2009-0913","article-title":"New intrauterine growth curves based on US data","volume":"125","author":"Olsen","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.ajog.2019.07.037_bib22","unstructured":"Product Information. Vivitrol. Alkermes Pharmaceuticals, 2010. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021897s015lbl.pdf. Last accessed January 24, 2019."},{"key":"10.1016\/j.ajog.2019.07.037_bib23","doi-asserted-by":"crossref","first-page":"1990201","DOI":"10.1111\/j.1521-0391.2012.00229.x","article-title":"Acceptance of naltrexone by pregnant women enrolled in comprehensive drug addiction treatment: an initial survey","volume":"21","author":"Jones","year":"2012","journal-title":"Am J Addict"},{"key":"10.1016\/j.ajog.2019.07.037_bib24","doi-asserted-by":"crossref","first-page":"B5","DOI":"10.1016\/j.ajog.2019.03.022","volume":"221","author":"Ecker","year":"2019","journal-title":"Am J Obstet Gynecol"}],"updated-by":[{"DOI":"10.1016\/j.ajog.2022.04.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937819309445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937819309445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:37:05Z","timestamp":1696984625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937819309445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0002937819309445"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2019.07.037","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ajog.2022.04.003","asserted-by":"object"}]},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of naltrexone in treating opioid use disorder in pregnancy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2019.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}